Galectin Therapeutics Financial Overview
Galectin Therapeutics's market cap is currently $370.11M. The company's EPS TTM is $-0.13; its P/E ratio is -9.71; Galectin Therapeutics is scheduled to report earnings on November 14, 2025, and the estimated EPS forecast is $-0.10. See an overview of income statement, balance sheet, and cash flow financials.
